🇺🇸 FDA

Intelligence · Clinical Pipeline

HOFFMANN-LA ROCHE Pipeline

All ClinicalTrials.gov programs at HOFFMANN-LA ROCHE — phase, modality, and trial IDs.

Programs
286

Quick answer

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  2. A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  3. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  4. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  5. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  6. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  7. A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  8. A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

    Hoffmann-La Roche

    Stable Coronary Artery Disease (CAD)

    phase 1 other active

    1 trial

  9. A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  10. An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

    Hoffmann-La Roche

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial

  11. An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  12. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  13. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  14. Ipatasertib

    Hoffmann-La Roche

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  15. Midazolam

    Hoffmann-La Roche

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  16. Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

    Hoffmann-La Roche

    Healthy Overweight or Obese

    phase 1 other active

    1 trial

  17. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  18. PEG-IFN alfa-2a BA-free formulation (Test)

    Hoffmann-La Roche

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. Placebo - MAD

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  20. RO5323441

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  21. RO5503781

    Hoffmann-La Roche

    Neoplasms

    phase 1 small molecule completed

    1 trial

  22. RO5503781 MBP

    Hoffmann-La Roche

    Myelogenous Leukemia, Acute

    phase 1 small molecule completed

    1 trial

  23. RO7119929

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  24. RO7507062

    Hoffmann-La Roche

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

  25. Rugonersen

    Hoffmann-La Roche

    Angelman Syndrome (AS)

    phase 1 small molecule active

    1 trial

  26. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  27. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial

  28. atorvastatin

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  29. balapiravir [RO4588161]

    Hoffmann-La Roche

    Dengue

    phase 1 small molecule completed

    1 trial

  30. danoprevir

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  31. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  32. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    approved small molecule completed

    1 trial

  33. Evrysdi 0.75 mg/mL powder for oral solution, RO7034067

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  34. Ganciclovir

    Hoffmann-La Roche

    Cytomegalovirus Infections

    approved small molecule completed

    1 trial

  35. Hemlibra 150 mg/mL solution for injection

    Hoffmann-La Roche

    Severe or Moderate Hemophilia A

    approved small molecule active

    1 trial

  36. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]

    approved small molecule active

    1 trial

  37. PEG-IFN alfa-2a

    Hoffmann-La Roche

    Hepatitis C, Chronic

    approved small molecule completed

    1 trial

  38. RO7034067, Evrysdi 0.75 mg/mL powder for oral solution

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  39. Satralizumab 120 mg

    Hoffmann-La Roche

    Neuromyelitis Optica Spectrum Disorder

    approved small molecule terminated

    1 trial

  40. Vabysmo 120 mg/mL solution for injection

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration

    approved small molecule active

    1 trial

  41. Vemurafenib

    Hoffmann-La Roche

    Neoplasms

    approved small molecule completed

    1 trial

  42. docetaxel

    Hoffmann-La Roche

    Breast Cancer

    approved small molecule completed

    2 trials

  43. epoetin beta [NeoRecormon]

    Hoffmann-La Roche

    Anemia

    approved small molecule terminated

    1 trial

  44. ibandronate [Bonviva/Boniva]

    Hoffmann-La Roche

    Post Menopausal Osteoporosis

    approved small molecule completed

    1 trial

  45. methoxy polyethylene glycol-epoetin beta [Mircera]

    Hoffmann-La Roche

    Anemia

    approved small molecule terminated

    2 trials

  46. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Gastric Cancer

    approved small molecule terminated

    1 trial

Frequently asked questions

How many pipeline programs does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.